References
Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A. In vitro and in vivo evaluation of [123J]JBZM: a potential CNS D-2 dopamine receptor imaging agent.J Nucl Med 1989; 30: 88–92.
Costa DC, Verhoeff NPLG, Cullum ID, Ell PJ, Syed GMS, Barrett J, Palazidou E, Toone B, Van Royen E, Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans.Eur J Nucl Med 1990; 16: 813–816.
Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Muller C, Deecke L. Dopamine D2 receptor imaging with SPELT: studies in different neuropsychiatric disorders.J Cereb Blood Flow Metab 1991; 11: 220–228.
Kung HF, Tromposch KM, Blau M. A new brain perfusion imaging agent: N,N,N′-trimethyl-N′-(2 hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine (HIPDM).J Nucl Med 1983; 29: 66, 72.
Kuhl DE, Barrio JR, Huang SC, et al. Quantifying local cerebral blood flow by N-isopropyl-p-[Jodine-123]-iodoamphetamine (IMP) tomography.J. Nucl Med 1982; 23: 196–203.
Ell PJ, Lui D, Cullum I, Jarritt PH, Donaghy M, Harrison MJG. Cerebral blood flow studies with123iodine-labelled amines.Lancet 1983; 1: 1348–1352.
Crawley JCW, Smith T, Veall N, Zanelli GD, Crow TJ, Owen F. Dopamine receptors displayed in living human brain with77Br-p-bromospiperone.Lancet 1983; 1: 975.
Wagner HN, Burner HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by PET.Science 1983; 221: 1264–1266.
Rights and permissions
About this article
Cite this article
Ell, P.J. Milestones. Eur J Nucl Med 23, 1441 (1996). https://doi.org/10.1007/BF01254464
Issue Date:
DOI: https://doi.org/10.1007/BF01254464